Primary bone lymphoma: tunisian multicentric retrospective study about 32 cases.

##plugins.themes.academic_pro.article.sidebar##

Published Sep 5, 2018
Download
pdf
Vol. 96 No. 5 (2018): Issue May 2018

##plugins.themes.academic_pro.article.main##

Chiraz Ben Ayed
Soumaya Laabidi
Najla Said
Mehdi Afrit
Selim Ben Ahmed
Hammouda Boussen

Abstract

Objective: To report the epidemiologic, clinical features, treatment modalities and prognosis of primary bone lymphomas (PBL) within a retrospective Tunisian series.
Patients and methods: We collected cases of histologically confirmed PBL in 3 medical oncology departments from northern and central Tunisia andwe analyzed their characteristics.
Results:  From January 1990 to July 2014, we collected 32 patients with histologically proven PBL, having a median age of 53 years. They affected mainly the long bones and diagnosed at early stages. 91% of the PBL were large cell B lymphoma.All patients received CHOP or CHOP-likeChemotherapy (CT), associated to Rituximab in the last 9 cases, with 14/32 patients received loco-regional radiotherapy and one patient had a resection-reconstruction surgery. We observed 90% of objective responses after primary CT.With a median follow-up of 38.5 months (1 to 192), the 5-year overall survival OS rate was 63%.18 patients relapsed and 14 remain alive in complete remission.
Conclusion: PBL remains a rare disease lately diagnosed in Tunisia. However, most of the patients had early stages tumors. Furthermore, the efficacy of CT and introduction of Rituximab leads to a high rate of complete/objective responses, improving the survival rate.

Keywords:

Lymphoma, bone, primary, B-cell, chemotherapy, rituximab, radiotherapy, response, survival.

##plugins.themes.academic_pro.article.details##

References

  1. Fletcher CD, Bridge JA, Hogendoorn P, Mertens F: WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: International Agency for Research on Cancer; 2013.
  2. Gianelli U, Patriarca C, Moro A, Ponzoni M, Giardini R, Massimino M et al. Lymphomas of the bone: a pathological and clinical study of 54 cases. Int J Surg Pathol 2002, 10:257-266.
  3. Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer; 2006:2652-6.
  4. Ramadan KM, Shenkier T, Sehn LH, Gascoyone RD, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18:129-35.
  5. Cai L, Stauder MC, Zhang Y-J, Poortmans P, Li Y. Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys. 2012; 83:284-91.
  6. Nasiri MRG, Varshoee F, Mohtashami S, Raziee HR, Aledavood A, Ghafarzadeh K. Primary bone lymphoma: a clinicopathological retrospective study of 28 patients in a single institution. J Res Med Sci 2011;16:814-20.
  7. Campanacci M. Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment. Springer Science;1999; 1346.
  8. Bhagavati S, Fu K. Primary Bone Lymphoma. Arch Pathol Lab Med. 2009; 133:1868-71.
  9. Schmidt-Tanguy A, Houot R, Lissandre S, Abgrall JF, Casassus P, Rodon P. Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma. Adv Hematol 2014;512508. doi: 10.1155/2014/512508.
  10. Christie D, Dear K, Le T, Barton M, Wirth A, Porter D. Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans- TasmanRadiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. Int J Radiat Oncol Biol Phys. 2011;80:1164-70.
  11. Ibrahim I, Haughom BD, Fillingham Y, Gitelis S. Is Radiation Necessary for Treatment of Non-Hodgkin's Lymphoma of Bone ? Clinical Results With Contemporary Therapy. Clin Orthop Relat Res. 2015 Apr 21.
  12. Barbieri E, Cammeli S, Mauro F, Perini F, Cazzola A, Neri S. Primary non-hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. Int J Radiat Oncol Biol Phys. 2004;59:760-4.
  13. Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D. Prognostic significance of soft tissue extension, International Prognostic Index, and multifocality in primary bone lymphoma: a single institutional experience. Br J Haematol. 2014 ;166:60-8.